Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

The Effect of Acupressure on Hyperbilirubinemia in Newborns: A Randomized Controlled Trial

NCT07409194 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-05-05
Last updated
2026-08-04

Condition(s) studied

Hyperbilirubinemia

Investigational drug(s) / intervention(s)

Acupressure

Acupressure: Acupressure intervention

Study summary

This study is a randomized controlled trial conducted to evaluate the effect of acupressure application on hyperbilirubinemia in newborns. The study examined the effect of regular acupressure applications to specific points on serum bilirubin levels in newborns at risk of developing physiological jaundice in the first days of life. By comparing bilirubin levels between the experimental and control groups, the potential benefits of acupressure in reducing the severity of jaundice and supporting bilirubin metabolism were investigated. The findings suggest that acupressure can be used as a complementary method in neonatal care.

Eligibility

Sex
ALL
Min age
38 Weeks
Max age
42 Months
Healthy volunteers
No
Inclusion Criteria: * Gestational age ≥38 weeks * Diagnosed with neonatal hyperbilirubinemia * Hospitalized in the neonatal unit for at least 24 hours * Birth weight ≥2500 g * Written informed consent obtained from parents Exclusion Criteria: * Preterm newborns * Congenital metabolic disease or congenital anomalies * Hemodynamically unstable newborns * Newborns whose parents did not provide consent * Newborns with any condition preventing acupressure application

Primary outcome measure(s)

  • Total Serum Bilirubin Level — 24 hours after birth
    Measurement of total serum bilirubin level to evaluate the effect of acupressure on neonatal hyperbilirubinemia.

Trial sites (1)

FacilityCityRegionStatus
Van Yuzuncu Yil University Van Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07409194 on ClinicalTrials.gov ↗ ← All trials in Turkey